Related Experiment Video
Updated: Jun 21, 2026

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
Published on: February 17, 2017
Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity
Maria Hatziapostolou1, Jean Delbe, Panagiotis Katsoris
1Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece.
Background:
The development and growth of human prostate cancer is mediated by many tumor cell-derived growth factors. Heparin affin regulatory peptide (HARP) seems to be involved in the progression of several tumors of diverse origin. In the present study, we sought to determine if HARP is implicated in human prostate cancer.
Methods:
An antisense strategy for inhibition of HARP expression in the human prostate cancer cell line LNCaP was used to study the role of HARP on cancer cell growth, migration, and angiogenic potential in vitro and in vivo.
Results:
Exogenous human recombinant HARP was mitogenic for LNCaP cells. By decreasing the expression of endogenous HARP, we found that HARP was essential for LNCaP cell migration, as well as anchorage-dependent and independent growth. Endothelial cell functions in vitro and blood vessel formation in vivo induced by LNCaP cells were also inhibited when HARP expression was diminished.
Conclusions:
HARP seems to act as an important regulator of diverse biological activities in human prostate cancer cells.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
07:13Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Related Concept Videos
Mitogens and the Cell Cycle
The Ras Gene
Ras is a superfamily...
Regulation of Angiogenesis and Blood Supply
PI3K/mTOR/AKT Signaling Pathway
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Anticoagulant Drugs: Low-Molecular-Weight Heparins